# A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC

> **NCT06617416** · PHASE3 · RECRUITING · sponsor: **Akeso** · enrollment: 560 (estimated)

## Conditions studied

- NSCLC (Non-small Cell Lung Cancer)

## Interventions

- **DRUG:** Cadonilimab (AK104)
- **DRUG:** Sugemalimab

## Key facts

- **NCT ID:** NCT06617416
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-12
- **Primary completion:** 2026-10-28
- **Final completion:** 2028-12-30
- **Target enrollment:** 560 (ESTIMATED)
- **Last updated:** 2025-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06617416

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06617416, "A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC". Retrieved via MORVS 2026-10-17 from https://api.morvs.ai/clinical/NCT06617416. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*